The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.
 
Emily Harrold
Consulting or Advisory Role - Pfizer
 
Henry S. Walch
No Relationships to Disclose
 
Walid Khaled Chatila
No Relationships to Disclose
 
Yelena Kemel
No Relationships to Disclose
 
Matilde Borio
No Relationships to Disclose
 
Anna Maio
No Relationships to Disclose
 
Aliya Khurram
No Relationships to Disclose
 
Erin E. Salo-Mullen
No Relationships to Disclose
 
Alicia Latham
No Relationships to Disclose
 
Yonina R. Murciano-Goroff
Employment - Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Research Funding - Andrew Sabin Family Foundation; Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); National Cancer Institute; National Cancer Institute; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Neil Howard Segal
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Novartis; Numab; PureTech; Revitope
Research Funding - AstraZeneca; Bristol-Myers Squibb; Immunocore; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Michael Bonner Foote
No Relationships to Disclose
 
Leonard B. Saltz
Consulting or Advisory Role - Genor BioPharma
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Nikolaus Schultz
No Relationships to Disclose
 
Diana Mandelker
No Relationships to Disclose
 
Andrea Cercek
Consulting or Advisory Role - Bayer; G1 Therapeutics; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Genentech/Roche (I); Gyroscope (I); Neurogene (I); Optos (I); Outlook Therapeutics (I); Regeneron (I); Regenxbio (I)